Trial reportNature medicine2018
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
Abstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 2 pooled it
18.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 2 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.Viruses · 2023Pooled it
- VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.The Journal of infectious diseases · 2025Trial
- Trial
- Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.Nature medicine · 2024Trial
- Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.PLoS medicine · 2024Trial
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.The lancet. HIV · 2024Trial
- Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.Nature medicine · 2022Trial
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.Nature medicine · 2022Trial
- SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.PLoS pathogens · 2022Trial
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.Nature medicine · 2021Trial
- CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.Frontiers in immunology · 2021Trial
- Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.The lancet. HIV · 2019Trial
- Trial
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.Nature medicine · 2026Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV.Nature microbiology · 2026Article
- HIV-1 Env Heterogeneity: Cleavage, Trafficking, and Antigenic Consequences for Virions and Infected Cells.Viruses · 2026Review
- Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.Nature microbiology · 2026Article
- Co-delivered PD-L1 rescues the protective efficacy mediated by an AAV-expressed HIV-1 bNAb.bioRxiv : the preprint server for biology · 2026Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
33 authors at 11 institutions in 2 countries.
Yotam Bar-OnLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Henning GruellLaboratory of Experimental Immunology, Institute of Virology, University Hospital Cologne, Cologne, Germany.
Till SchoofsLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Joy A PaiLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Lilian NogueiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Allison L ButlerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Katrina MillardLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Clara LehmannDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Isabelle SuárezDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Theodora KaragounisLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Yehuda Z CohenLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-6987-1478
Christoph WyenDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Stefan ScholtenPraxis Hohenstaufenring, Cologne, Germany.
Lisa HandlMethods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-1041-7948
Shiraz BelblidiaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Juan P DizonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Jörg J VehreschildDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Maggi Witmer-PackLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Irina ShimeliovichLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Kanika JainLaboratory of Experimental Immunology, Institute of Virology, University Hospital Cologne, Cologne, Germany.
Kerstin FiddikeDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Kelly E SeatonDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Nicole L YatesDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Jill HorowitzLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Roy M GulickDivision of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
Nico PfeiferMethods in Medical Informatics, Department of Computer Science, University of Tübingen, Tübingen, Germany.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, NC, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Gerd FätkenheuerDepartment I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.
Florian KleinLaboratory of Experimental Immunology, Institute of Virology, University Hospital Cologne, Cologne, Germany. florian.klein@uk-koeln.de.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.
Rockefeller University · USDuke University · USGerman Center for Infection Research · DEUniversity Hospital Cologne · DEUniversity of Cologne · DEBeth Israel Deaconess Medical Center · USCornell University · USFriedrich-Ebert-Stiftung e.V. · DEHoward Hughes Medical Institute · USMax Planck Institute for Informatics · DEUniversity of Tübingen · DE
Funding
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Kathryn M. Anastos · 2017 to 2026
$28.3MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MOptimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2MHoward Hughes Medical InstituteNIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI129795NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126620
Abstract
Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-prone HIV-1 replication leads to the production of drug-resistant viral variants
Indexed as
ImmunotherapyAdolescentAdultAgedAntibodies, NeutralizingAntiretroviral Therapy, Highly ActiveFemaleHIV-1HIV InfectionsHIV SeropositivityHumansMaleMiddle AgedViral LoadViremiaYoung AdultAntibodies, Neutralizing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.